329 related articles for article (PubMed ID: 36002850)
1. Intersecting substance use treatment and harm reduction services: exploring the characteristics and service needs of a community-based sample of people who use drugs.
Krawczyk N; Allen ST; Schneider KE; Solomon K; Shah H; Morris M; Harris SJ; Sherman SG; Saloner B
Harm Reduct J; 2022 Aug; 19(1):95. PubMed ID: 36002850
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
[No Abstract] [Full Text] [Related]
3. A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts.
Hassan R; Roland KB; Hernandez B; Goldman L; Evans KN; Gaul Z; Agnew-Brune C; Buchacz K; Fukuda HD
J Subst Abuse Treat; 2022 Jul; 138():108722. PubMed ID: 35067399
[TBL] [Abstract][Full Text] [Related]
4. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
[TBL] [Abstract][Full Text] [Related]
5. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
Krawczyk N; Fawole A; Yang J; Tofighi B
Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
[TBL] [Abstract][Full Text] [Related]
6. Harm reduction via online platforms for people who use drugs in Russia: a qualitative analysis of web outreach work.
Davitadze A; Meylakhs P; Lakhov A; King EJ
Harm Reduct J; 2020 Dec; 17(1):98. PubMed ID: 33298081
[TBL] [Abstract][Full Text] [Related]
7. Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives.
Austin EJ; Corcorran MA; Briggs ES; Frost MC; Behrends CN; Juarez AM; Frank ND; Healy E; Prohaska SM; LaKosky PA; Kapadia SN; Perlman DC; Schackman BR; Jarlais DCD; Williams EC; Glick SN
Int J Drug Policy; 2022 Nov; 109():103825. PubMed ID: 35977459
[TBL] [Abstract][Full Text] [Related]
8. The effects of COVID-19 on New York State's Drug User Health Hubs and syringe service programs: a qualitative study.
Ude M; Behrends CN; Kelly S; Schackman BR; Clear A; Goldberg R; Gelberg K; Kapadia SN
Harm Reduct J; 2023 Feb; 20(1):12. PubMed ID: 36732773
[TBL] [Abstract][Full Text] [Related]
9. "We'll be able to take care of ourselves" - A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs.
Frost T; Deutsch S; Brown S; Lemien E; Cunningham CO; Fox AD
Subst Abus; 2021; 42(4):983-989. PubMed ID: 33759722
[No Abstract] [Full Text] [Related]
10. Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020.
Behrends CN; Lu X; Corry GJ; LaKosky P; Prohaska SM; Glick SN; Kapadia SN; Perlman DC; Schackman BR; Des Jarlais DC
Drug Alcohol Depend; 2022 Mar; 232():109323. PubMed ID: 35124386
[TBL] [Abstract][Full Text] [Related]
11. Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial.
Watson DP; Swartz JA; Robison-Taylor L; Mackesy-Amiti ME; Erwin K; Gastala N; Jimenez AD; Staton MD; Messmer S
BMC Public Health; 2021 Mar; 21(1):630. PubMed ID: 33789642
[TBL] [Abstract][Full Text] [Related]
12. Substance use patterns, sociodemographics, and health profiles of harm reduction service recipients in Burlington, Vermont.
Erath TG; LaCroix R; O'Keefe E; Higgins ST; Rawson RA
Harm Reduct J; 2024 Apr; 21(1):76. PubMed ID: 38580997
[TBL] [Abstract][Full Text] [Related]
13. HIV Care Continuum Services for People Who Inject Drugs in Kazakhstan During COVID-19: A Qualitative Study of Service Provider Perspectives.
McCrimmon T; Sundelson A; Darisheva M; Gilbert L; Hunt T; Terlikbayeva A; Primbetova S; El-Bassel N
Glob Health Sci Pract; 2022 Apr; 10(2):. PubMed ID: 35487549
[TBL] [Abstract][Full Text] [Related]
14. Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study.
Suarez E; Bartholomew TS; Plesons M; Ciraldo K; Ostrer L; Serota DP; Chueng TA; Frederick M; Onugha J; Tookes HE
Ann Med; 2023 Dec; 55(1):733-743. PubMed ID: 36856571
[No Abstract] [Full Text] [Related]
15. Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.
Jakubowski A; Fowler S; Fox AD
Addict Sci Clin Pract; 2023 Jun; 18(1):40. PubMed ID: 37301953
[TBL] [Abstract][Full Text] [Related]
16. Unmet needs and harm reduction preferences of syringe services program participants: differences by co-use of illicit opioids and methamphetamine.
Sun R; Sauda TH; Hoopsick RA
Harm Reduct J; 2024 Jun; 21(1):119. PubMed ID: 38890736
[TBL] [Abstract][Full Text] [Related]
17. The impact of the COVID-19 pandemic on people who inject drugs accessing harm reduction services in an rural American state.
Thakarar K; Kohut M; Hutchinson R; Bell R; Loeb HE; Burris D; Fairfield KM
Harm Reduct J; 2022 Jul; 19(1):80. PubMed ID: 35869523
[TBL] [Abstract][Full Text] [Related]
18. A qualitative study exploring the impact of the COVID-19 pandemic on People Who Inject Drugs (PWID) and drug service provision in the UK: PWID and service provider perspectives.
May T; Dawes J; Fancourt D; Burton A
Int J Drug Policy; 2022 Aug; 106():103752. PubMed ID: 35653821
[TBL] [Abstract][Full Text] [Related]
19. Toward a human-centered use of technology: a stakeholder analysis of harm reduction and CBO staff.
Aronson ID; Bennett AS; Freeman R
Harm Reduct J; 2020 Oct; 17(1):77. PubMed ID: 33076911
[TBL] [Abstract][Full Text] [Related]
20. Promoting Safe Injection Practices, Substance Use Reduction, Hepatitis C Testing, and Overdose Prevention Among Syringe Service Program Clients Using a Computer-Tailored Intervention: Pilot Randomized Controlled Trial.
Hochstatter KR; Hull SJ; Sethi AK; Burns ME; Mundt MP; Westergaard RP
J Med Internet Res; 2020 Sep; 22(9):e19703. PubMed ID: 32990630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
